Amgen Posts Mixed Third-Quarter Results, Sales of Epogene Nosedive
Amgen posted mixed third-quarter results Monday. Though the firm’s top line and bottom line increased by 3% each, Amgen’s performance was bolstered by a lower tax rate and reduced shares outstanding (lower earnings quality growth), while being muddied by a large legal charge. Nonetheless, we are maintaining our $80+ fair value estimate, as we think our long-term projections remain in the ballpark. The firm’s top line expansion was led by a 9% increase in international product sales. Combined Neulasta and Neupogene sales jumped 6%, while US sales of Xgeva, the firm’s new cancer drug, reached $100 million in the quarter following its recent launch. Sales of Sensipar/Mimpara jumped 18%, sales of Vectibix jumped 13%, and sales of Nplate increased 28%. … Read more